Compare Stocks → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BDRXNASDAQ:GRINASDAQ:LSDINASDAQ:PBLA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$0.96$1.09$0.67▼$11.19$1.24M1.537.21 million shs203,953 shsGRIGRI Bio0.30-8.7%0.480.29▼47.95$1.14M-1.55542,950 shs185,600 shsLSDILucy Scientific Discovery$0.83-3.5%$1.06$0.44▼$12.80$1.46M1.253.73 million shs74,612 shsPBLAPanbela Therapeutics$0.40+5.3%$0.47$0.35▼$210.00$1.39M1.5540,073 shs28,390 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals0.00%-6.37%-22.23%-29.09%-85.65%GRIGRI Bio0.00%-5.03%-29.60%-63.17%-99.28%LSDILucy Scientific Discovery0.00%-5.05%-1.43%-54.61%-92.56%PBLAPanbela Therapeutics0.00%+11.11%+4.90%-68.50%-99.70%This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDRXBiodexa Pharmaceuticals2.744 of 5 stars3.54.00.00.03.30.01.3GRIGRI BioN/AN/AN/AN/AN/AN/AN/AN/ALSDILucy Scientific DiscoveryN/AN/AN/AN/AN/AN/AN/AN/APBLAPanbela Therapeutics0.6933 of 5 stars3.30.00.00.01.10.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals3.00Buy$8.00729.53% UpsideGRIGRI BioN/AN/AN/AN/ALSDILucy Scientific Discovery3.00BuyN/AN/APBLAPanbela Therapeutics2.50Moderate Buy$500.00124,900.00% UpsideCurrent Analyst RatingsLatest LSDI, PBLA, BDRX, and GRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2024PBLAPanbela TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral3/27/2024PBLAPanbela TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$410K3.03N/AN/A$3.93 per share0.25GRIGRI BioN/AN/AN/AN/A0.74 per shareN/ALSDILucy Scientific Discovery$16.73K87.14N/AN/A$2.86 per share0.29PBLAPanbela TherapeuticsN/AN/AN/AN/A($0.92) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$7.66MN/A0.00N/AN/AN/AN/AN/AN/AGRIGRI Bio-$13.04MN/A0.00∞N/AN/A-548.12%-290.50%8/12/2024 (Estimated)LSDILucy Scientific Discovery-$8.99M-$7.00N/A∞N/AN/A-294.74%-137.65%6/5/2024 (Estimated)PBLAPanbela Therapeutics-$25.26M-$280.98N/AN/AN/AN/A-70,194.55%-207.79%N/ALatest LSDI, PBLA, BDRX, and GRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024Q1 2024PBLAPanbela Therapeutics-$1.23-$2.28-$1.05-$2.28N/AN/A5/10/2024Q1 2024GRIGRI BioN/A-0.46-0.46-0.46N/AN/A3/26/2024Q4 2023PBLAPanbela Therapeutics-$24.34-$65.90-$41.56-$65.90N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/ALSDILucy Scientific DiscoveryN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa Pharmaceuticals0.061.261.26GRIGRI BioN/A2.642.64LSDILucy Scientific DiscoveryN/A0.380.38PBLAPanbela TherapeuticsN/A0.170.17OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%GRIGRI Bio33.95%LSDILucy Scientific Discovery72.61%PBLAPanbela Therapeutics4.37%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%GRIGRI Bio2.96%LSDILucy Scientific DiscoveryN/APBLAPanbela Therapeutics0.01%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals211.29 million1.28 millionNot OptionableGRIGRI Bio43.77 million3.66 millionNot OptionableLSDILucy Scientific Discovery21.77 millionN/ANot OptionablePBLAPanbela Therapeutics73.48 million3.48 millionNot OptionableLSDI, PBLA, BDRX, and GRI HeadlinesRecent News About These CompaniesMay 25, 2024 | nasdaq.comPanbela Therapeutics Inc. (PBLA) Insider ActivityMay 17, 2024 | msn.comHC Wainwright & Co. Downgrades Panbela Therapeutics (PBLA)May 16, 2024 | uk.finance.yahoo.comQ1 2024 Panbela Therapeutics Inc Earnings CallMay 16, 2024 | msn.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finance.yahoo.comPanbela Therapeutics Inc (PBLA) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...May 15, 2024 | globenewswire.comPanbela Provides Business Update and Reports Q1 2024 Financial ResultsMay 6, 2024 | finance.yahoo.comPanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacMay 6, 2024 | globenewswire.comPanbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacMay 1, 2024 | globenewswire.comPanbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024April 30, 2024 | globenewswire.comAcceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekApril 22, 2024 | globenewswire.comPanbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025April 18, 2024 | marketwatch.comPanbela Applies to List on CBOEApril 18, 2024 | globenewswire.comPanbela Announces Poster Presentation at American Association for Cancer Research:April 17, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Panbela Announces Transfer to OTCQB MarketApril 16, 2024 | finance.yahoo.comPanbela Announces Transfer to OTCQB MarketMarch 28, 2024 | benzinga.comRecap: Panbela Therapeutics Q4 EarningsMarch 28, 2024 | seekingalpha.comPanbela Therapeutics, Inc. (PBLA) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | msn.comPanbela Therapeutics, Inc. (NASDAQ:PBLA) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finanznachrichten.dePanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsMarch 26, 2024 | globenewswire.comPanbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiodexa PharmaceuticalsNASDAQ:BDRXBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing products aimed at primary and metastatic cancers of the brain in the United Kingdom. The company is developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. In addition, the company offers licensing for MTD 201 (Q-octreotide) and MTD211 (Q-brexpiprazole). The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.GRI BioNASDAQ:GRIGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Lucy Scientific DiscoveryNASDAQ:LSDILucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada.Panbela TherapeuticsNASDAQ:PBLAPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.